Quick answer: The most common side effects of retatrutide are gastrointestinal, especially nausea, diarrhea, constipation, and vomiting. These symptoms appear to be dose-related and may be more noticeable during dose escalation. Newer clinical trial data also include reports of dysesthesia, or unusual skin sensations, which patients should discuss with a clinician.
For patients researching advanced weight loss medications, understanding retatrutide side effects is an important part of evaluating the treatment. Retatrutide, sometimes referred to informally online as “reta” or “reta peptide,” is an investigational triple receptor agonist developed by Eli Lilly that targets GLP-1, GIP, and glucagon receptors.
In Phase 3 TRIUMPH-1 data, participants receiving the highest studied dose of 12 mg lost an average of 28.3% of their body weight at 80 weeks, while a prespecified extension involving participants with a baseline BMI of at least 35 reported average weight loss of 30.3% at 104 weeks. However, retatrutide remains investigational and is not FDA-approved or available by prescription outside clinical trials.
At BODYWELLE in Miami Beach, I help patients evaluate evidence-based weight management options by considering potential benefits, side effects, medical history, and individual treatment goals.
Key Takeaways About Retatrutide Side Effects
- Gastrointestinal symptoms, including nausea, diarrhea, constipation, and vomiting, are the most commonly reported retatrutide side effects.
- Retatrutide side effects appear to be dose-related, with higher doses generally linked to more frequent or noticeable symptoms.
- Dysesthesia, or unusual skin sensations such as tingling or altered sensitivity, has been reported in newer retatrutide clinical trial data.
- Most side effects reported in clinical trials have been mild to moderate and may improve as the body adjusts during dose escalation.
- Retatrutide remains investigational and is not FDA-approved, so patients should only consider it within legitimate clinical trial settings.
Most Common Retatrutide Side Effects
Nausea
Gastrointestinal side effects remain the most frequently reported adverse events in retatrutide clinical trials, with nausea among the most common. In Phase 3 TRIUMPH-1 data, nausea was reported in 28.6% of participants taking 4 mg, 38.4% taking 9 mg, and 42.4% taking 12 mg, compared with 14.8% of participants receiving placebo. This dose-related pattern is consistent with how GLP-1-based therapies can slow gastric emptying and increase feelings of fullness during treatment.
Vomiting, Diarrhea, and Constipation
Vomiting, diarrhea, and constipation were also commonly reported in retatrutide clinical trials, particularly at higher studied doses. In Phase 3 TRIUMPH-1 data, diarrhea was reported in 25.2% to 34.1% of participants taking retatrutide, constipation in 23.8% to 26.1%, and vomiting in 10.6% to 25.3%, compared with lower rates among participants receiving placebo. These gastrointestinal issues were generally consistent with the side effect profile seen across incretin-based therapies.
Dysesthesia
Dysesthesia refers to unusual skin sensations, such as tingling, prickling, burning, or altered sensitivity. In Phase 3 TRIUMPH-1 data, dysesthesia occurred in 5.1%, 12.3%, and 12.5% of participants taking retatrutide 4 mg, 9 mg, and 12 mg, compared with 0.9% of participants receiving placebo. Patients should discuss these symptoms with a qualified clinician, especially if they are persistent, worsening, or uncomfortable.
Headaches and Injection Site Reactions
Headaches and injection site reactions, including mild redness or irritation at the weekly injection site, were also documented in trial participants, though these were less commonly reported than gastrointestinal symptoms.
How to Manage and Minimize Retatrutide Side Effects
Mild gastrointestinal symptoms may occur during treatment with incretin-based therapies, particularly during dose escalation. Because retatrutide remains investigational, I recommend that patients discuss potential side effects with a qualified medical professional and avoid using products marketed outside legitimate clinical trial settings.
- Dose Escalation and Tolerability: In clinical trials, gastrointestinal side effects were more common during dose escalation and at higher doses. Phase 2 data suggest that a lower starting dose may improve tolerability. Because retatrutide remains investigational, dosing should follow an authorized clinical trial protocol.
- Eat Smaller, More Frequent Meals: To combat nausea, avoid eating large volumes at once. Stop eating as soon as you feel full, as this class of medication slows gastric emptying.
- Stay Adequately Hydrated: Drinking plenty of water throughout the day is crucial, especially if you experience transient diarrhea or vomiting, to maintain kidney function and prevent dehydration.
- Avoid Trigger Foods: Limit greasy, highly processed, or extremely spicy foods, as these can exacerbate gastrointestinal irritation and bloating during the dose adjustment period.
At BODYWELLE, I use individualized treatment planning and careful follow-up to help patients manage side effects with appropriate, currently available weight management options.
Other Safety Considerations and Potential Risks
The safety information below includes both adverse events observed in retatrutide clinical trials and potential risks considered based on related incretin-based medications. These should be distinguished from long-term or very rare risks that are still unknown because retatrutide remains investigational.
Allergic Reactions
Allergic reactions are uncommon but require prompt medical attention. Patients should seek immediate evaluation for symptoms such as difficulty breathing, facial or throat swelling, widespread rash, or significant skin changes that go beyond a typical injection site reaction.
Gallbladder Disease and Pancreatitis
Gallbladder problems, including gallstones, have been associated with significant weight loss and with GLP-1-based therapies more broadly. Pancreatitis is also a rare but serious condition that remains an important monitored safety concern. Severe or persistent abdominal pain, especially if accompanied by vomiting or systemic symptoms, should be evaluated promptly.
Thyroid-Related Safety Considerations
Because retatrutide remains investigational, its final FDA-approved warnings and contraindications have not been established. Some approved medications that act on the GLP-1 receptor carry warnings or contraindications related to medullary thyroid carcinoma and multiple endocrine neoplasia syndrome type 2 (MEN2). Whether similar labeling will apply to retatrutide will depend on the completed safety data and regulatory review.
Heart Rate and Laboratory Changes
A notable finding in retatrutide trials has been an increase in resting heart rate during treatment. Phase 2 data showed dose-dependent increases in heart rate that peaked around week 24 and declined thereafter. Changes in liver enzymes and other laboratory measures have also been evaluated as part of the drug’s evolving safety profile. Clinical trials continue to monitor participants for cardiovascular, hepatic, renal, metabolic, and other potential safety concerns as researchers gather more information about retatrutide.
Start Your Journey to Success, Don’t Wait Any Longer!
Join our satisfied clients who’ve experienced safe, effective treatments.
What We Still Don’t Know About Retatrutide Side Effects
Although multiple Phase 3 retatrutide trials have now reported results, its long-term safety profile and very rare adverse effects are still being established. Retatrutide remains investigational, and continued clinical research is needed to identify risks that may only become apparent with longer treatment or broader use.
Lilly has reported positive Phase 3 results from TRIUMPH-1, as well as TRIUMPH-2 and TRIUMPH-3. Lilly currently plans to submit a Biologics License Application for retatrutide to the FDA in the first quarter of 2027. However, retatrutide has not been FDA-approved, and regulatory review has not yet occurred.
How Retatrutide Works and Why Gastrointestinal Symptoms Occur
Retatrutide is an investigational triple receptor agonist that activates GLP-1, GIP, and glucagon receptors. This mechanism distinguishes it from semaglutide, which primarily targets GLP-1, and tirzepatide, which targets GLP-1 and GIP. By acting on these hormone pathways, retatrutide may influence appetite, blood sugar regulation, energy balance, and metabolic function.
Retatrutide has also been shown to delay gastric emptying, meaning food moves more slowly through the stomach. This effect may help explain why nausea, vomiting, bloating, constipation, and other digestive symptoms can occur, particularly during dose escalation or at higher doses. These symptoms are not unique to retatrutide and are commonly seen across GLP-1-based therapies.
The Benefits of Retatrutide in Context
Understanding retatrutide side effects requires weighing tolerability against the medication’s clinical potential. In newer Phase 3 data, retatrutide produced substantial average body weight reduction at higher studied doses, reinforcing why the medication has attracted significant attention in obesity medicine. However, because retatrutide remains investigational, its benefits must be interpreted alongside its evolving safety profile, dose-related side effects, and the need for ongoing clinical monitoring.
Schedule Your Weight Loss Consultation at BODYWELLE
Retatrutide remains an investigational medication and is not currently FDA-approved or available by prescription outside legitimate clinical trials. For patients with questions about retatrutide, GLP-1 medications, or medically supervised weight management, the first step is a thorough clinical evaluation.
At BODYWELLE in Miami Beach, I review each patient’s metabolic profile, health history, current medications, and treatment goals to determine which evidence-based options may be appropriate. Depending on the patient, this may include established weight management strategies, currently available prescription medications, lifestyle support, or continued monitoring of emerging therapies as clinical data evolves.
Schedule your consultation at BODYWELLE in Miami Beach to explore safe, medically supervised options for weight loss and metabolic health.
